

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Lung Committee

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Yingqi Zhao, PhD
 Mary Redman, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease: Tina Cascone, MD, PhD
 Shirish Gadgil, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals: Lisa G. Davis, RN
 Patient Advocate: Barbara Martin, MS
 Pharmaceutical Science: Safae Ghouraichi, PharmD
 Michael Leung, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager: Jennifer Beeler, MA (Lung-MAP)
 Clinical Trials Program Manager: Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Friday, October 9, 2026 11:30 a.m. - 1:30 p.m.
 Room: Regency A (Ballroom Level)

Agenda

General Updates & Announcements: Jhanelle E. Gray, MD

Upcoming Meetings and Deadlines

Keynote #1: AACR Plenary/WCLC Presidential Encore Presentation
 Chad Rusthoven, MD

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Megan Daly, MD

Translational Medicine Session: Ignacio Wistuba, MD

Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN

Imaging: Chadwick Wright, MD

Patient Advocate Update: Barbara Martin

Keynote #2: WCLC Encore Presentation: Maya Khalil, MD

Thoracic Medical Oncology: Jhanelle Gray, MD

S2409, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Activated: 9/8/25; Accrual Goal: 900; Accrual: 32. Anne Chiang, MD and Alberto Chiappori

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 14. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3983. Karen Reckamp, MD and David R. Gandara, MD

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 8/3/26. Dr. Jonathan Riess and Dr. Susan Scott

Lung Committee

S1900J, "A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study)." Activated: 9/27/24; Accrual goal: 88; Accrual: 18; 4 (revision 1). Shirish Gadgeel, MD and Christian Rolfo, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Activated: 4/28/25; Accrual Goal: 378; Accrual: 123. Saiama Waqar, MD, MSCI and Tina Li, MD

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 35; 28 (revision 1). Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Activated: 12/18/2023; Accrual Goal: 56; Accrual: 29. Paul Paik, MD and Xiuning Le, MD, PhD

Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Reckamp, Waqar, Redman, et al. Activation: 1/28/19.

S1900G, "A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1900J, "A Phase II Study of Amivantamab Hyaluronidase in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell

Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel. Activation: 9/27/24.

S1900N, "A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Scott and Riess.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li. Activation: 4/28/25.

S2409, "PRISM: PReclison in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang, Chiappori, Kim, et al. Activation: 9/8/25.

S2414, "A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated: 10/22/20.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients

Lung Committee

Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.

S1900F, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of

Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20. Permanently closed to accrual: 12/15/25.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20. Permanently closed to accrual: 2/15/26.

S2302, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.

Lung Committee

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local

Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A

Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EAS191, "A Randomized Phase II Trial of Cabozantinib and

Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and

Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900P, "A Randomized Phase II Selection Design of Sapanisertib and Paclitaxel with or without Serabelisib in Participants with NRF2 or PI3K Pathway-Positive Stage IV or Recurrent Squamous Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Paik and Riano.

S1900Q, "A Phase II Study of Zongertinib and Trastuzumab Deruxtecan in Participants with HER2-Positive Stage IV Non-Small Cell Lung Cancer (Alliance Lung-MAP Sub-Study)." Drs. Parikh and Doroshov.

S2608, "Sequencing of Immunotherapy and Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Randomized Phase III Study (SIMON)." Dr. Park.

S2612, "A Phase II Study of Atezolizumab and JBI-802 for Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC)." Drs. Tseng and Puri.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

LUNGMAP Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators Doroshov DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono DE, Leighl NB, Li BT, Li T, Mack PC, Neal JW, Paik PK, Patel SP, Riess JW, Redman MW, Reckamp KL. Journal of Clinical Oncology [Comments and Controversies]. 2026. <https://pubmed.ncbi.nlm.nih.gov/42234933/>

S1914 A Randomized Phase III Trial of Induction and Consolidation Atezolizumab with Stereotactic Body Radiation Therapy versus Radiation Alone in High Risk, Early-Stage Non-Small Cell Lung Cancer (SWOG/NRG S1914). Daly ME, Simone II SB, Redman MW, Hsieh M, Hesketh PJ, Hu C., Monjazeb AM, Steuer CE, Ganti AK, Kashani R, Bauman JR, Feliciano JL, Moon J, Ku K, Le-Lindqwister N, Baschnagel AM, Maraboyina S, Sherwood GB, Almquist D, Higgins KA, Gray JE, Bradley JD, Kelly K. Accepted 2026.

Submitted Manuscripts

S0424 Exposures, Tumor Factors and Survival by Sex and Smoking Status in Non-Small Cell Lung Cancer A Prospective Case-Series Trial (SWOG S0424, NCI NCTN). Albain K, Moon J, Ambrosone C, Darke A, Hsieh M, Santella R, Cheng TYD, Holland W, Borczuk A, Chay CH, Morris PT, Vallieres E, Kratzke R, Molina JR, Kolesar JM, Chen Y, Matsumoto S, Reid M, Zirpoli G, Davis W, Ondracek R, Bshara W, Omilian A, Gray J, Kelly K, Lara PN, Redman M, Gandara D, Mack P. Submitted 2025.

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900G	S1900J	S1900K	S1933	S2409	S2414
Arnot Ogden Medical Center/Falck Cancer Center	7	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	48	6	3	-	1	1	1	-	2
Baylor College of Medicine/Duncan Comp Cancer Center	-	-	5	-	-	-	-	-	-
Boston Medical Center	-	-	7	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	2	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	4	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	59	1	-	-	-	-	4	-	-
Cancer Research of Wisconsin & N Michigan Consort	39	-	7	-	-	-	-	-	1
Carle Cancer Center NCI Comm Oncology Research Prgrm	3	-	1	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	2	-	-	-	-	-	-
Cedars-Sinai Medical Center	21	-	-	1	-	-	-	-	-
City of Hope Comprehensive Cancer Center	7	2	1	-	-	-	-	-	-
Columbia University NCI Comm Oncology Research Prgrm	13	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	28	-	6	-	-	-	-	-	-
CommonSpirit Health Research Institute	41	-	1	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	4	3	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	1
Essentia Health NCI Comm Oncology Research Program	18	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	8	-	-	4	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-
Georgia CaRes	6	-	1	-	-	-	1	-	-
Georgia NCI Community Oncology Research Program	83	8	3	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	1	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	20	-	3	-	-	-	-	-	-
Hartford Hospital	4	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	160	2	9	-	-	-	5	-	-
Henry Ford Hospital	20	-	-	-	-	-	1	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	1	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	8	-	-	-	-	-	-
Intermountain Medical Center	1	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgam	97	1	-	-	-	1	-	-	-
Kansas City Veterans Affairs Medical Center	5	1	-	-	-	-	-	-	-
Lahey Clinic	35	-	-	-	-	-	2	-	1
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-
Loyola University Medical Center	28	2	-	-	-	-	-	1	-
Malcom Randall Veterans Administration Medical Cntr	23	1	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Info Cntr	66	1	4	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	28	-	-	1	-	-	-	1	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	131	2	4	2	-	-	-	1	-
Mission Hospital	1	-	-	-	-	-	-	-	-
Moffitt Cancer Center	23	1	1	1	-	2	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	LUNGMAP	S1800E	S1827	S1900G	S1900J	S1900K	S1933	S2409	S2414
Montana Cancer Consortium NCORP	10	-	1	-	-	-	1	-	-
Mount Sinai Braman Comprehensive Cancer Center	2	-	-	-	-	-	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	-	-	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-
Northwestern University LAPS	39	4	1	2	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	2	-	-	-	-	1	-	-	-
Oregon Health and Science University	14	-	-	1	-	2	-	-	1
Our Lady of the Lake Hospital	4	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-	1
Salem Hospital	7	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	57	-	8	-	-	1	-	1	1
Sutter Cancer Research Consortium	79	-	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	13	-	-	-	-	-	-	-	-
The Hawaii NCORP	29	-	2	-	1	-	-	-	-
The Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-	-
The NCI Comm Oncology Research Prgrm: The New Mex NCORP	119	-	1	-	-	-	1	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	113	3	1	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cncr Cntr	32	2	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	18	1	-	-	-	1	-	-	-
UPMC Hillman Cancer Center LAPS	98	3	12	-	-	-	6	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	7	-	-	-	-	-	-
University of Arizona LAPS	1	1	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	49	3	1	1	-	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	1	1	1	-	-	-
University of Kentucky/Markey Cancer Center	67	7	1	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	38	5	1	-	-	-	18	-	-
University of Rochester LAPS	68	-	-	-	-	2	-	1	-
University of Texas MD Anderson Cancer Center LAPS	3	-	7	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	3	2	4	-	-	1	-	-	-
Upstate Carolina Consort Comm Oncology Research Prgrm	42	-	3	-	-	-	-	-	1
Wayne State University/Karmanos Cancer Institute	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	45	-	4	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	34	4	5	4	-	-	-	-	-
ALLIANCE	942	23	29	3	1	4	5	-	-
CCTG	-	-	39	-	-	-	-	-	-
ECOG-ACRIN	410	12	11	2	-	11	-	3	1
NRG	548	10	89	3	-	1	2	1	-
Total	4,036	111	304	27	4	29	48	9	10

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A081801	A082002	A151216	EA5162	EA5182	EA5221	EA5231	NRGLU008	S2402
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	1	-	1	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	4	-	26	-	2	-	-	2	1
Baylor College of Medicine/Duncan Comp Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	3	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	25	-	59	-	1	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	5	-	-	-	-	-	-
Columbia University NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	-	-	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	2	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	3	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	8	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Program	1	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	15	3	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-
Georgia CaRes	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	10	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	1	-	1	-	-	-	-	-	1
Hartford Hospital	-	-	-	-	2	-	1	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	2	-	44	1	-	-	-	-	-
Houston Methodist Hospital	-	-	8	-	2	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	1	-	3	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Prgam	7	-	208	-	8	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	1	-	-	-	-
Lahey Clinic	1	-	30	-	-	-	1	-	-
Loma Linda University Medical Center	-	-	10	-	-	-	-	-	-
Loyola University Medical Center	2	-	26	-	-	-	-	-	-
Malcom Randall Veterans Administration Medical Cntr	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Info Cntr	13	-	34	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	11	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	28	-	83	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A081801	A082002	A151216	EA5162	EA5182	EA5221	EA5231	NRGLU008	S2402
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	1	-	3	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	8	-	24	-	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	4	-	-	-	-	-	-
Regents of the University of Michigan	-	-	51	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	1	11	-	-	-	-	3	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-
The Brown Cancer Center at University of Louisville	-	-	5	-	-	-	-	-	-
The NCI Comm Oncology Research Prgrm: The New Mex NCORP-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	1	-	31	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cncr Cntr	-	-	15	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	5	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	12	-	-	-	-	-	-
University of Arizona LAPS	-	-	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	3	-	-	1	-	-	-
U of California Davis Comprehensive Cancer Center	1	2	46	-	1	-	-	-	-
U of Cincinnati Cancer Center-UC Medical Center	-	-	24	-	1	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	58	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	1	5	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	26	-	-	-	-	-	-
University of Nebraska Medical Center	1	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	5
University of Rochester LAPS	-	-	-	-	-	2	-	-	1
University of Texas MD Anderson Cancer Center LAPS	-	-	2	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	1	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	1	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	7	-	57	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	109	4	986	4	26	4	2	5	8

